-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
STAS is Associated with Poor Prognosis in Early-Stage NSCLC Regardless of Surgical Approach
JCOG0802/WJOG4607L data validate segmentectomy as non-inferior to lobectomy, regardless of the presence of STAS, Dr. Yasushi Yatabe said.
-
Novel Meta-Analysis Shows VATS Improves Overall Survival in Early-Stage Lung Cancer
Dr. Jacie Jiaqi Law shared results from a first-ever meta-analysis demonstrating that VATS reduces mortality risk without compromising disease-free survival.
-
New Data Warrant Broader Lung Cancer Screening Guidelines
Dr. Elaine Shum said the FANSS trial data confirm the feasibility of expanding screening to high-risk individuals with no smoking history.
-
Survival Benefit Found in Screening Surgically Fit Patients Up to Age 80
Findings from Dr. Patrick Goodley suggest that older patients who can undergo surgery may achieve survival benefits similar to younger patients.
-
Lessons from ECOG-ACRIN E4512: Could Limited Gains Lead to Positive Direction in Refining Adjuvant Therapy?
Discussant Dr. Jessica L. Lin said the results won’t change clinical practice after Dr. David Gerber reported no differences in OS or DFS.
-
Ivonescimab-Chemotherapy Combo Shows Promise as Post-TKI Option in EGFR-Mutant NSCLC
Dr. Jonathan W. Goldman reported that ivonescimab plus chemotherapy yielded a consistent PFS benefit across subgroups.
-
ARROS-1 Findings Reinforce Potential of Zidesamtinib in Pretreated ROS1-Altered NSCLC
The highly ROS1-selective TKI showed durable responses in previously treated patients with ROS1-altered NSCLC, according to data presented by Dr. Alexander E. Drilon.
-
Aumolertinib Plus Chemo Shows Modest PFS Gain Over Monotherapy for EGFR/TSG-Mutant NSCLC
Investigator Dr. Jie Wang presented results from the first-of-its-kind trial comparing combination therapy with monotherapy in this patient population.
-
Perioperative Nivolumab Proves Safe, Effective for Patients with Resectable Early-Stage NSCLC
Dr. Jonathan Spicer shared patient-reported outcomes data from CheckMate 77T showing the regimen is both safe and tolerable for patients.
-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
Dr. Mariano Provencio said the results could potentially define a standard adjuvant treatment for patients with resectable ES-NSCLC; however, longer-term observation is needed.